Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study

@article{Currier2008AntiviralAA,
  title={Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study},
  author={Judith S. Currier and Adriano Lazzarin and Louis Sloan and Nathan Clumeck and Jihad Slims and Debra Mccarty and Helen M Steel and J. P. Kleim and Tab Bonny and Judith Millard},
  journal={Antiviral Therapy},
  year={2008},
  volume={13},
  pages={297 - 306}
}
Background This Phase IIb study explored the antiviral activity and safety of the investigational CCR5 antagonist aplaviroc (APL) in antiretroviral-naive patients harbouring R5-tropic virus. Methods One hundred and forty-seven patients were randomized 2:2:1 to one of two APL dosing regimens or efavirenz (EFV). All dosage arms were administered twice daily and in combination with lamivudine/zidovudine (3TC/ZDV; Combivir, COM). Efficacy, safety, and pharmacokinetic parameters were assessed… 

Figures and Tables from this paper

Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism
TLDR
The acquisition of the M184V mutation is the primary characteristic of virologic failure in first-line therapy with aplaviroc plus lamivudine-zidovudine plusCombivir, regardless of the envelope tropism.
Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
TLDR
Maraviroc was generally safe in treatment-experienced participants for >5 years and rates of death and selected clinical events were low during follow-up.
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
TLDR
Results of the meta-analysis showed that efavirenz-based regimens were equally effective as other recommended regimens based on NNRTI, ritonavir-boosted PI or CCR5 antagonist in terms of efficacy outcomes, which support the present clinical guidelines for antiretroviral-naive, HIV-infected patients.
Optimal use of maraviroc in clinical practice.
Maraviroc belongs to a new class of anti-HIV drugs named CCR5 antagonists, which block HIV entry into cells. It has proven potent efficacy in treatment-experienced patients with multiple drug
HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
TLDR
This study shows that R5 HIV-1 strains resistant to CCR5 inhibitors can arise in patients, confirming a mechanism of resistance previously characterized in vitro and suggesting implications for the clinical use of this new class of antiretrovirals.
Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials
TLDR
This review found that over 90% of patients remained on an EFV-based first-line regimen after an average follow-up time of 78 weeks, and the relative risk of discontinuations due to adverse events was higher for EFV compared with most other first- line options, but absolute differences were less than 5% for all comparisons.
Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data
TLDR
This review will provide a summative overview of the incidence and medications associated with hepatic adverse reactions linked to the use of contemporary antiretroviral drugs.
CCR5 Antagonists: Host-Targeted Antiviral Agents for the Treatment of HIV Infection, 4 Years on
TLDR
The field is revisited and the clinical and virological data that have emerged in the 4 years since are assessed, with particular reference to maraviroc for which the most comprehensive data currently exist.
Resistance against inhibitors of HIV-1 entry into target cells
ABSTRACT  HIV resistance against currently approved entry inhibitors, the chemokine receptor-5 (CCR5) antagonist maraviroc and the fusion inhibitor enfuvirtide (T-20), manifests in a complex manner
...
...

References

SHOWING 1-10 OF 37 REFERENCES
Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)
TLDR
The mechanism for the idiosyncratic hepatotoxicity observed in the clinical trials of APL is unknown but is likely intrinsic to the molecule rather than its novel mechanism of action.
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults
TLDR
873140 demonstrated potent antiretroviral activity and was well tolerated following short-term monotherapy in HIV-infected adults and support further evaluation in Phase 2b/3 studies.
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
TLDR
The activity and durable suppression of HIV-1 observed in this study is probably attributable to the observed tolerability profile and the achievement of high ABT-378 plasma concentrations.
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
TLDR
Observations suggest that plasma drug levels attained with high-dose nevirapine were not sufficient to inhibit ne virapine-resistant virus, although they were approximately 2-fold higher than reported IC50 values of resistant virus.
Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail
TLDR
Mild inhibition of CYP3A isozymes should not preclude the use of concomitant CYP2D6 substrates in future clinical studies with aplaviroc, and metabolite‐to‐parent urinary excretion ratio (dextrorphan/dextromethorphan) was determined.
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.
TLDR
Baseline CD4 cell count, pVL, HIV-1 V3 sequence, and CCR5 Delta 32 genotype were the strongest determinants of CXCR4-using HIV- 1 in this population of antiretroviral-naive individuals.
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
  • T. WilkinZ. Su R. Gulick
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
TLDR
Infection with dual-tropic or mixed HIV-1 populations that use both CCR5 and CX CR4 is common among highly treatment-experienced patients, but infection with virus using CXCR4 alone is uncommon.
Simultaneous determination of zidovudine and lamivudine in human serum using HPLC with tandem mass spectrometry.
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected individuals
  • AIDS
  • 2005
Drug induced liver disease.
  • M. Black
  • Medicine
    Postgraduate medical journal
  • 1983
...
...